What is the recommended management of symptomatic anemia, including criteria for red‑cell transfusion and appropriate use of iron, vitamin B12, folate, and erythropoiesis‑stimulating agents?

Management of Symptomatic Anemia

For symptomatic anemia, immediately transfuse red blood cells if hemoglobin is <7-8 g/dL or if severe symptoms are present at any hemoglobin level, while simultaneously investigating and treating the underlying cause with iron replacement (intravenous preferred for complex patients) and avoiding erythropoiesis-stimulating agents in most settings except specific cancer populations.

Immediate Assessment and Red Blood Cell Transfusion

When to Transfuse

Use a restrictive transfusion threshold of 7-8 g/dL in most hospitalized patients, including those with coronary heart disease 1. This approach is as safe as liberal transfusion strategies and reduces complications. However, transfuse immediately regardless of hemoglobin level if:

• Severe anemia-related symptoms are present (dyspnea at rest, chest pain, altered mental status, hemodynamic instability)
• Hemoglobin <7-8 g/dL in most patients 2, 3

Critical exception: In patients with acute coronary syndromes or active myocardial infarction, evidence is limited and clinical judgment based on symptoms should guide transfusion decisions rather than strict thresholds 4.

Transfusion Practice

• Transfuse single units and reassess rather than multiple units 3
• Red blood cells of any storage time are acceptable 3
• Transfusion provides immediate hemoglobin increase in 100% of patients but carries risks of transfusion reactions, circulatory overload, immunosuppression, and potential infection transmission 2

Diagnostic Workup for Underlying Cause

Before initiating specific anemia therapy, obtain:

• Iron studies: Ferritin, transferrin saturation (TSAT), serum iron
  • Absolute iron deficiency: Ferritin <100 ng/mL, TSAT <20%
  • Functional iron deficiency: Ferritin >100 ng/mL but TSAT <20%
• Renal function: Creatinine, GFR (assess for chronic kidney disease)
• Vitamin levels: B12 and folate
• Inflammatory markers: CRP (elevated suggests anemia of inflammation)
• Reticulocyte count: Determines if anemia is regenerative
• Complete blood count with MCV: Guides differential diagnosis 5, 3

Iron Replacement Therapy

Intravenous Iron (Preferred for Most Complex Patients)

Intravenous iron is the treatment of choice for absolute iron deficiency in patients with complex medical disorders 4, 6. Use IV iron when:

• Absolute iron deficiency (ferritin <100 ng/mL) is present
• Functional iron deficiency (TSAT <20%, ferritin >100 ng/mL) in patients receiving chemotherapy
• Oral iron intolerance or poor response is anticipated
• Rapid hematologic response is needed
• Gastrointestinal absorption is impaired 2

Dosing: Administer 1000 mg iron as single dose or divided doses according to specific formulation labels. Available preparations include ferric carboxymaltose (up to 1000 mg per week, 15-minute infusion), iron isomaltoside (up to 1000 mg, 15-minute infusion), iron sucrose (200-500 mg per dose), and ferric gluconate (125 mg per dose) 2.

In cancer patients receiving cardiotoxic chemotherapy: Give IV iron before or after (not same day as) chemotherapy administration 2.

Oral Iron

Consider oral iron only for:

• Stable patients with absolute iron deficiency (ferritin <100 ng/mL)
• Non-inflammatory conditions (CRP <5 mg/L)
• No gastrointestinal pathology affecting absorption 2

Oral iron is less effective in inflammatory states due to hepcidin upregulation blocking iron absorption 2.

Erythropoiesis-Stimulating Agents (ESAs)

When ESAs Are Contraindicated (Strong Recommendations)

Do NOT use ESAs in:

• Heart disease patients with mild-to-moderate anemia and congestive heart failure or coronary heart disease (strong recommendation, moderate-quality evidence) 1
• Cancer patients receiving curative-intent chemotherapy 7, 5, 7
• Most patients with non-chemotherapy-associated anemia 7, 5
• Critically ill patients for routine anemia management 3, 8

The evidence shows ESAs increase thrombotic events, hypertension, and potentially mortality in these populations without meaningful clinical benefit 1, 7.

Limited Appropriate Use of ESAs

ESAs may be offered only in these specific scenarios:

Cancer patients:

• Chemotherapy-associated anemia with non-curative treatment intent
• Hemoglobin declined to <10 g/dL
• RBC transfusion remains an alternative option 7, 5, 7

Myelodysplastic syndromes:

• Lower-risk MDS (IPSS low to intermediate-1)
• Serum erythropoietin level ≤500 IU/L 7, 5

Dosing when ESAs are used:

• Epoetin alfa: 450 IU/kg subcutaneously once weekly or 150 IU/kg three times weekly
• Darbepoetin alfa: 500 μg (6.75 μg/kg) subcutaneously every 3 weeks or 2.25 μg/kg weekly
• Target hemoglobin: Lowest concentration needed to avoid transfusions (not a specific number) 7, 2, 7

Discontinue ESAs if no response (1-2 g/dL hemoglobin increase) within 6-8 weeks and reassess for iron deficiency or disease progression 7, 2.

ESAs with Iron Supplementation in Cancer

In cancer patients receiving ESAs, add IV iron therapy for functional iron deficiency (TSAT <20%, ferritin >100 ng/mL) to improve hematopoietic response and reduce transfusion requirements 5, 2. Growing evidence supports this combination approach over ESA monotherapy.

Vitamin Supplementation

• Vitamin B12: Replace if deficient (typically <200 pg/mL)
• Folate: Replace if deficient (typically <2 ng/mL)
• These are straightforward replacements when deficiency is documented 3, 6

Critical Pitfalls to Avoid

1. Do not use ESAs in heart disease patients - this increases mortality and thrombotic events without benefit 1
2. Do not delay transfusion in severely symptomatic patients while waiting for iron or ESA response 2
3. Do not use oral iron in inflammatory states - hepcidin blocks absorption, making it ineffective 2
4. Do not continue ESAs beyond 8 weeks without response - reassess for other causes 7, 2
5. Do not use ESAs in critically ill patients routinely - no mortality benefit and potential harm 3, 8
6. Do not target specific "normal" hemoglobin levels with ESAs - use lowest level to avoid transfusions 7

Special Populations

Trauma patients: Consider erythropoietin therapy in absence of contraindications 3

Hematologic malignancies (myeloma, lymphoma, CLL): Observe hematologic response to cancer treatment before considering ESA; exercise particular caution with thrombotic risk 7, 5

Critically ill patients: Restrictive transfusion threshold of <70 g/L recommended, including those with ARDS and septic shock 9